Pyxis: Downgrading To 'Hold' After PYX-106 Dropped And Continued HNSCC Advancement MICVO

🇺🇸 Seeking Alpha (US) —

AI Summary

The article reports a downgrade of Pyxis to 'Hold' after the company dropped PYX-106 while continuing to advance MICVO for head and neck squamous cell carcinoma. It focuses on the company's development pipeline and the financial implications of its clinical and strategic decisions.

Markets Health Pyxis PYX-106 MICVO HNSCC drug development stock downgrade clinical pipeline

Read original source →